Last reviewed · How we verify
Ethylthioperazine (THIETHYLPERAZINE)
At a glance
| Generic name | THIETHYLPERAZINE |
|---|---|
| Sponsor | Novartis |
| Drug class | thiethylperazine |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1961 |
Approved indications
- Nausea
- Nausea and vomiting
- Vomiting
Common side effects
Key clinical trials
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Tick-borne Encephalitis and Borrelial Antibodies in Serum (NA)
- Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers (PHASE2)
- Observational Study of Perioperative Chemotherapy in Gastric Cancer
- Tick-borne Encephalitis and Positive Borrelial Antibodies (NA)
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (PHASE3)
- Aseptic Meningoencephalitis in Slovenia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethylthioperazine CI brief — competitive landscape report
- Ethylthioperazine updates RSS · CI watch RSS
- Novartis portfolio CI